2012

2/2/12 -Spherix Announces Registered Direct Offering Of $1.15 Million

1/11/12 -Spherix Announces Successful Completion of Important Toxicology Study of SPX-106 Readies IND Filing

2011

11/16/11 -Spherix Issues Reminder Of Business Update Conference Call Set For Today At Noon Eastern Time

11/11/11 -Spherix Announces Third Quarter Financial Results - Conference Call To Be Held On November 16 At 12 Noon ET -

10/28/11 -Spherix Announces Closing Of Private Placement of $1.25 Million Discusses Use Of Proceeds

10/26/11 -Spherix To Raise $1.25 Million In Private Placement

10/24/11 -Spherix Announces Results From New Preclinical Studies Showing SPX-106T Produces Significant Reductions In Cholesterol, Fat Deposition and Body Weight

Additional Info (Click Here)

10/24/11 - SPHERIX ANNOUNCES RESULTS FROM NEW PRECLINICAL STUDIES SHOWING SPX-106T PRODUCES SIGNIFICANT REDUCTIONS IN CHOLESTEROL, FAT DEPOSITION AND BODY WEIGHT

9/8/11 - SPX-106T Treatment Yields Significant Reductions In Serum VLDL and LDL Cholesterol In Mice

9/6/11 - Spherix Incorporated To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

8/12/11 - Spherix Announces Second Quarter Financial results - Conference Call To Be Held On August 18 at Noon ET

6/21/11 - Spherix Announces Annual Shareholders Meeting Date

6/13/11 - Spherix To Present At The 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference On June 16

6/2/11 - Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing

5/24/11 - Spherix Regains Compliance With NASDAQ Listing Rule

5/13/11 - Spherix Announces First Quarter Financial Results

5/6/11 - Spherix Announces Reverse Stock Split Effective May 6, 2011

4/19/11 - Spherix To Effect Reverse Stock Split

3/30/11 - Spherix Announces 2010 Financial Results Business Update Call to be Held April 7 at 11:00 a.m. Eastern Time

3/22/11 - Spherix To Present At The BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference

2/8/11 - Spherix To Present At The 13th Annual BIO CEO & Investor Conference

1/24/11 - Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants

1/20/11 - Spherix Announces Registered Direct Offering of $2.77 Million

1/05/11 - Spherix to Present at Two Upcoming Prominent Finance Conferences

2010

12/09/10 - Spherix Phase 2 Trial with D-Tagatose Determines Minimum Dose for HBA1C and Triglycerides

12/08/10 - Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-Tagatose in Lowering Triglycerides

12/06/10 - Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 P.M. Eastern Time

12/02/10 - Spherix Announces Post-HOC Analysis of Phase 3 Trial With D-Tagatose in Diabetes

11/15/10 - Spherix Announces Third Quarter 2010 Financial Results

11/03/10 - Spherix Awarded Grant from U.S. Goverment Under the Patient Protection and Affordable Care Act

10/12/10 - Spherix Announces Closing of Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants

10/07/10 - Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants

10/07/10 - Spherix Announces Statistically Significant Results in Phase 3 Study With D-Tagatose in Type 2 Diabetes

09/15/10 - Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development

08/31/10 - Spherix's 2010 Annual Shareholder Meeting Script

08/20/10 - Spherix Inc.'s new direction illustrates importance of adjusting quickly to wrenching shifts in biotech

08/17/10 - Spherix Announces Second Quarter 2010 Finacial Results

06/30/10 - Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy

06/24/10 - Spherix Seeks Sweeter Road to Market with Sugar Drug

06/23/10 - Spherix Expands Development Strategy for D-Tagatose Seeks Pharma Partner For Continued Development in Diabetes

05/03/10 - Spherix to Present at 2010 BIO International Convention in Chicago

04/01/10 - Spherix Announces 2009 Financial Results

01/12/10 - Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes

01/11/10 - Spherix To Present at Annual Onemedplace Finance Forum and at EBD Biotech Showcase In San Francisco

2009

11/19/09 - Spherix Announces Results of Annual Shareholders Meeting

11/19/09 - Spherix Announces the Closing of $6.3 Million Registered Direct Offering

11/16/09 - Spherix Reports Third Quarter 2009 Earnings

11/16/09 - Spherix Incorporated to Raise $6.3 Million in Registered Direct Offering

11/16/09 - Spherix Announces Positive Interim Results In Phase 3 Trial of Novel, Oral Compound for Type 2 Diabetes

11/13/09 - Spherix Incorporated to Webcast Formal Remarks from Annual Meeting of Shareholders

09/23/09 - Spherix Incorporated Announces Annual Shareholders Meeting Date

09/10/09 – Spherix Incorporated Appoints Dr. Ram Nimmagudda as Director of New Business Development

09/03/09 – Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

08/17/09 – Spherix Reports Second Quarter 2009 Earnings

06/24/09 – Spherix Announces Positive Phase 2 Study Results

06/23/09 – Spherix Announces Termination of Arla License Agreement

06/23/09 – Spherix Announces Full-Scale Production of Pharmaceutical Tagatose

05/22/09 – Spherix Regains Full NASDAQ Compliance

05/14/09 – Spherix Reports First Quarter 2009 Earnings

05/14/09 – Spherix Elects New Independent Director, and Elects Chairman of the Board

05/14/09 – Spherix to Exhibit at the BIO International 2009 Convention

04/27/09 – Spherix Recruiting New “Independent” Director to Regain NASDAQ Compliance

04/17/09 – Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board

03/31/09 – Spherix Incorporated Holds 2008 Earnings Conference Call

03/30/09 – Spherix Announces 2008 Financial Results

03/11/09 – Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data

2008

11/19/08 – Spherix Stockholders Authorize Potential Reverse Stock Split

11/13/08 – Spherix Reports 3rd Quarter Earnings

11/10/08 – Spherix Transfers Stock Listing to NASDAQ Capital Market

11/07/08 – Patient Recruitment Begins in India for Phase 3 Diabetes Trial

10/23/08 – Spherix Receives NASDAQ Letter Extending Minimum Bid Price Compliance Person

09/08/08 – Spherix Incorporated to Seek Stockholder Approval of Reverse Stock Split

08/14/08 – Spherix Reports 2nd Quarter Earnings

07/23/08 – Spherix Receives NASDAQ Bid Price Deficiency Letter

07/14/08 – Spherix Expands Phase 3 Naturlose® Diabetes Trial Outside of the U.S.

05/14/08 – Spherix Reports 1st Quarter Earnings

05/14/08 – Spherix Holds Annual Shareholders Meeting

05/12/08 – Market Research Shows Spherix’s Naturlose® Readily Accepted by Diabetes Patients; Meets MD’s Treatment Need

04/30/08 – Spherix D-Tagatose to be Supplied by Inalco S.p.A.

04/17/08 – Spherix Hires Key Employees

04/03/08 – Spherix Reports 2007 Financial Results

2007

11/29/07 – Growth Achieved in Spherix’s Health Sciences Business

11/16/07 – Spherix Reports 3rd Quarter Earnings

08/16/07 – Spherix Shareholders Support Company’s Focus on Naturlose®, Biotechnology

08/14/07 – Spherix Reports Second Quarter Earnings

08/09/07 – Spherix Launches Health Sciences Consulting Business Line

06/27/07 – Spherix Signs Definitive Agreement for Sale of Information Subsidiary

05/14/07 – Spherix Reports 1st Quarter Earnings

05/01/07 – Spherix Announces Start of Phase 3 Clinical Trial

04/26/07 – Spherix Signs Letter of Intent for the Sale of its Information Subsidiary

03/30/07 – Spherix Reports Record 2006 Financial Results

02/22/07 – InfoSpherix Adds Golf Package to its ReserveWorld Business Line